Cargando…

Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer

BACKGROUND: It remains unknown to what extent consensus molecular subtype (CMS) groups and immune-stromal infiltration patterns improve our ability to predict outcomes over tumor–node–metastasis (TNM) staging and microsatellite instability (MSI) status in early-stage colorectal cancer (CRC). PATIENT...

Descripción completa

Detalles Bibliográficos
Autores principales: Dienstmann, R, Villacampa, G, Sveen, A, Mason, M J, Niedzwiecki, D, Nesbakken, A, Moreno, V, Warren, R S, Lothe, R A, Guinney, J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6857614/
https://www.ncbi.nlm.nih.gov/pubmed/31504112
http://dx.doi.org/10.1093/annonc/mdz287
_version_ 1783470802670190592
author Dienstmann, R
Villacampa, G
Sveen, A
Mason, M J
Niedzwiecki, D
Nesbakken, A
Moreno, V
Warren, R S
Lothe, R A
Guinney, J
author_facet Dienstmann, R
Villacampa, G
Sveen, A
Mason, M J
Niedzwiecki, D
Nesbakken, A
Moreno, V
Warren, R S
Lothe, R A
Guinney, J
author_sort Dienstmann, R
collection PubMed
description BACKGROUND: It remains unknown to what extent consensus molecular subtype (CMS) groups and immune-stromal infiltration patterns improve our ability to predict outcomes over tumor–node–metastasis (TNM) staging and microsatellite instability (MSI) status in early-stage colorectal cancer (CRC). PATIENTS AND METHODS: We carried out a comprehensive retrospective biomarker analysis of prognostic markers in adjuvant chemotherapy-untreated (N = 1656) and treated (N = 980), stage II (N = 1799) and III (N = 837) CRCs. We defined CMS scores and estimated CD8+ cytotoxic lymphocytes (CytoLym) and cancer-associated fibroblasts (CAF) infiltration scores from bulk tumor tissue transcriptomes (CMSclassifier and MCPcounter R packages); constructed a stratified multivariable Cox model for disease-free survival (DFS); and calculated the relative proportion of explained variation by each marker (clinicopathological [ClinPath], genomics [Gen: MSI, BRAF and KRAS mutations], CMS scores [CMS] and microenvironment cells [MicroCells: CytoLym+CAF]). RESULTS: In multivariable models, only ClinPath and MicroCells remained significant prognostic factors, with both CytoLym and CAF infiltration scores improving survival prediction beyond other markers. The explained variation for DFS models of ClinPath, MicroCells, Gen markers and CMS4 scores was 77%, 14%, 5.3% and 3.7%, respectively, in stage II; and 55.9%, 35.1%, 4.1% and 0.9%, respectively, in stage III. Patients whose tumors were CytoLym high/CAF low had better DFS than other strata [HR=0.71 (0.6–0.9); P = 0.004]. Microsatellite stable tumors had the strongest signal for improved outcomes with CytoLym high scores (interaction P = 0.04) and the poor prognosis linked to high CAF scores was limited to stage III disease (interaction P = 0.04). CONCLUSIONS: Our results confirm that tumor microenvironment infiltration patterns represent potent determinants of the risk for distant dissemination in early-stage CRC. Multivariable models suggest that the prognostic value of MSI and CMS groups is largely explained by CytoLym and CAF infiltration patterns.
format Online
Article
Text
id pubmed-6857614
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-68576142019-11-20 Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer Dienstmann, R Villacampa, G Sveen, A Mason, M J Niedzwiecki, D Nesbakken, A Moreno, V Warren, R S Lothe, R A Guinney, J Ann Oncol Original Articles BACKGROUND: It remains unknown to what extent consensus molecular subtype (CMS) groups and immune-stromal infiltration patterns improve our ability to predict outcomes over tumor–node–metastasis (TNM) staging and microsatellite instability (MSI) status in early-stage colorectal cancer (CRC). PATIENTS AND METHODS: We carried out a comprehensive retrospective biomarker analysis of prognostic markers in adjuvant chemotherapy-untreated (N = 1656) and treated (N = 980), stage II (N = 1799) and III (N = 837) CRCs. We defined CMS scores and estimated CD8+ cytotoxic lymphocytes (CytoLym) and cancer-associated fibroblasts (CAF) infiltration scores from bulk tumor tissue transcriptomes (CMSclassifier and MCPcounter R packages); constructed a stratified multivariable Cox model for disease-free survival (DFS); and calculated the relative proportion of explained variation by each marker (clinicopathological [ClinPath], genomics [Gen: MSI, BRAF and KRAS mutations], CMS scores [CMS] and microenvironment cells [MicroCells: CytoLym+CAF]). RESULTS: In multivariable models, only ClinPath and MicroCells remained significant prognostic factors, with both CytoLym and CAF infiltration scores improving survival prediction beyond other markers. The explained variation for DFS models of ClinPath, MicroCells, Gen markers and CMS4 scores was 77%, 14%, 5.3% and 3.7%, respectively, in stage II; and 55.9%, 35.1%, 4.1% and 0.9%, respectively, in stage III. Patients whose tumors were CytoLym high/CAF low had better DFS than other strata [HR=0.71 (0.6–0.9); P = 0.004]. Microsatellite stable tumors had the strongest signal for improved outcomes with CytoLym high scores (interaction P = 0.04) and the poor prognosis linked to high CAF scores was limited to stage III disease (interaction P = 0.04). CONCLUSIONS: Our results confirm that tumor microenvironment infiltration patterns represent potent determinants of the risk for distant dissemination in early-stage CRC. Multivariable models suggest that the prognostic value of MSI and CMS groups is largely explained by CytoLym and CAF infiltration patterns. Oxford University Press 2019-10 2019-08-27 /pmc/articles/PMC6857614/ /pubmed/31504112 http://dx.doi.org/10.1093/annonc/mdz287 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Original Articles
Dienstmann, R
Villacampa, G
Sveen, A
Mason, M J
Niedzwiecki, D
Nesbakken, A
Moreno, V
Warren, R S
Lothe, R A
Guinney, J
Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer
title Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer
title_full Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer
title_fullStr Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer
title_full_unstemmed Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer
title_short Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer
title_sort relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage ii/iii colorectal cancer
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6857614/
https://www.ncbi.nlm.nih.gov/pubmed/31504112
http://dx.doi.org/10.1093/annonc/mdz287
work_keys_str_mv AT dienstmannr relativecontributionofclinicopathologicalvariablesgenomicmarkerstranscriptomicsubtypingandmicroenvironmentfeaturesforoutcomepredictioninstageiiiiicolorectalcancer
AT villacampag relativecontributionofclinicopathologicalvariablesgenomicmarkerstranscriptomicsubtypingandmicroenvironmentfeaturesforoutcomepredictioninstageiiiiicolorectalcancer
AT sveena relativecontributionofclinicopathologicalvariablesgenomicmarkerstranscriptomicsubtypingandmicroenvironmentfeaturesforoutcomepredictioninstageiiiiicolorectalcancer
AT masonmj relativecontributionofclinicopathologicalvariablesgenomicmarkerstranscriptomicsubtypingandmicroenvironmentfeaturesforoutcomepredictioninstageiiiiicolorectalcancer
AT niedzwieckid relativecontributionofclinicopathologicalvariablesgenomicmarkerstranscriptomicsubtypingandmicroenvironmentfeaturesforoutcomepredictioninstageiiiiicolorectalcancer
AT nesbakkena relativecontributionofclinicopathologicalvariablesgenomicmarkerstranscriptomicsubtypingandmicroenvironmentfeaturesforoutcomepredictioninstageiiiiicolorectalcancer
AT morenov relativecontributionofclinicopathologicalvariablesgenomicmarkerstranscriptomicsubtypingandmicroenvironmentfeaturesforoutcomepredictioninstageiiiiicolorectalcancer
AT warrenrs relativecontributionofclinicopathologicalvariablesgenomicmarkerstranscriptomicsubtypingandmicroenvironmentfeaturesforoutcomepredictioninstageiiiiicolorectalcancer
AT lothera relativecontributionofclinicopathologicalvariablesgenomicmarkerstranscriptomicsubtypingandmicroenvironmentfeaturesforoutcomepredictioninstageiiiiicolorectalcancer
AT guinneyj relativecontributionofclinicopathologicalvariablesgenomicmarkerstranscriptomicsubtypingandmicroenvironmentfeaturesforoutcomepredictioninstageiiiiicolorectalcancer